Luigi Celio
0000-0001-6849-9838
Azienda Socio Sanitaria Territoriale del Garda
62 papers found
Refreshing results…
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study
Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy
Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy
Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: An evidence-based review of safety, efficacy, and place in therapy
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron?
Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials
Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
Research on Chemotherapy-Induced Nausea: Back to the Past for an Unmet Need?
Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer Analysis of a Phase II Trial
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials
Palonosetron: An Evidence-Based Choice in Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy
Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: A multi-institutional phase II study
Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer
Missing publications? Search for publications with a matching author name.